Table 2 Characteristics of the patients with HF.
All HF | non-obese HF | obese HF | ||
|---|---|---|---|---|
(N = 40) | (N = 27) | (N = 13) | P | |
Age, y | 64 ± 9 | 63 ± 10 | 66 ± 7 | 0.305 |
Sex, Female, % (F/M) | 12 (5/35) | 15 (4/23) | 8 (1/12) | 0.653 |
BMI | 27.6 ± 5.1 | 24.8 ± 2.6 | 33.2 ± 4.6. | <0.001 |
Cardiovascular risk factors | ||||
Hypertensive, % (n) | 40 (16) | 41 (11) | 39 (5) | 1.000 |
T2-Diabetes, % (n) | 35 (14) | 22 (6) | 61 (8) | 0.031 |
Dyslipedemia, % (n) | 45 (18) | 37 (10) | 61 (8) | 0.185 |
Smoking, % (n) | 10 (4) | 11 (3) | 8 (1) | 1.000 |
Heart failure etiology | ||||
Ischemic CM, % (n) | 60 (24) | 56 (15) | 69 (9) | 0.503 |
Valvular CM, % (n) | 5 (2) | 7 (2) | 0 (0) | 0.550 |
Dilated CM, % (n) | 35 (14) | 37 (10) | 31(4) | 0.740 |
Medication | ||||
ACEIs, % (n) | 72 (29) | 74 (20) | 69 (9) | 1.000 |
ARBs, % (n) | 15 (6) | 11 (3) | 23 (3) | 0.370 |
Beta-blockers, % (n) | 90 (36) | 92 (25) | 85 (11) | 0.583 |
Diuretics, % (n) | 67 (27) | 74 (20) | 53 (7) | 0.100 |
Vitamin K antagonists, % (n) | 45 (18) | 52 (14) | 31 (4) | 0.312 |
Antiplatelet agents, % (n) | 67 (27) | 63 (17) | 77 (10) | 0.484 |
Statines, % (n) | 65 (26) | 59 (16) | 77 (10) | 0.316 |
Admission labs | ||||
BNP, pmol/ml | 450 [245–957] | 614 [326–1487] | 214 [127–774] | 0.073 |
Creatinine, μmol/l | 101 [96–124] | 103 [93–134] | 100 [82–143] | 0.817 |
C reactive protein, mg/l | 7.8 [3.5–11.6] | 8.1 [2.7–13.6] | 7.8 [3.3–14.7] | 0.858 |
Na+ mM | 138 ± 3 | 138 ± 3 | 138 ± 3 | 0.523 |
ALT, U/ml | 29 [25–36] | 26 [19–38] | 32 [26–48] | 0.311 |
Admission vitals | ||||
Mean Blood Pressure, mmHg | 86 ± 12 | 83 ± 11 | 91 ± 12 | 0.035 |
Heart rate, Bpm | 73 ± 16 | 75 ± 16 | 70 ± 17 | 0.449 |
Echocardiography | ||||
LVEF, % | 31 ± 13 | 27 ± 10 | 39 ± 13 | 0.003 |
LVEF < 30%, % (n) | 42 (17) | 52 (14) | 23 (3) | 0.103 |
NYHA class | ||||
II, % (n) | 60 (24) | 55 (15) | 69 (9) | 0.503 |
III, % (n) | 35 (14) | 37 (10) | 31(4) | 0.740 |
IV, % (n) | 5 (2) | 4 (1) | 8 (1) | 1.000 |
